ReviewThe Yale journal of biology and medicine2025
Nanotechnology-driven Epigenetic Cancer Therapy: Precision Delivery and Sustained Release of DNA Methylation Modulators.
Review in The Yale journal of biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Epigenetic pacemaker: A review of DNA methylation, histone lactylation, and non-coding RNAs in autoimmune skin diseases.Journal of translational autoimmunity · 2026Review
- Immune-epigenetic convergence in biomaterial-guided tissue regeneration.Materials today. Bio · 2026Article
- Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.Journal of hematology & oncology · 2026Review
- DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions.Epigenomics · 2026Review
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer.Cell death discovery · 2026Review
- Exploring the Impact of Nanotherapeutics on Histone H3 and H4 Acetylation Enrichment in Cancer Epigenome: A Systematic Scoping Synthesis.Epigenomes · 2025Review
- PLGA-based nanoparticles in colorectal cancer immunotherapy: current concepts and future perspectives.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant DNA methylation contributes to cancer by silencing tumor suppressor genes and facilitating tumor growth. DNA methyltransferase inhibitors (DNMTis), including 5-azacytidine (5-AZA) and decitabine (DAC), can potentially mitigate these consequences and revive gene expression. Their therapeutic effectiveness is hindered by factors like poor bioavailability, swift degradation, and unintended toxicity. Advances in nanotechnology enable targeted DNMTi delivery, enhancing efficacy while minimizing toxicity. This mini-review explores several key types of nanoformulations for DNMTi delivery, including PLGA nanoparticles, liposomes, solid lipid nanoparticles (SLNs), bentonite-based nanoparticles, gold nanoparticles (AuNPs), amphiphilic prodrugs, PEGylated nanoparticles, bionic nanoparticles, gelatinase-sensitive nanoparticles, and chitosan-based pH-responsive systems. This paper emphasizes the integration of epigenetic therapies and nanotechnology in oncology, focusing on the creation of nanocarriers for precise delivery of methylation modulators and new formulations for prolonged drug release. By addressing these advancements, the review underscores the potential of nanotechnology to revolutionize epigenetic cancer therapy, offering new hope for improved patient outcomes in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.